Insider Buying: Roquefort Therapeutics plc (LON:ROQ) Insider Purchases 400,000 Shares of Stock

Roquefort Therapeutics plc (LON:ROQ) insider Stephen Paul West acquired 400,000 shares of the company’s stock in a transaction on Tuesday, February 4th. The stock was purchased at an average cost of GBX 3 ($0.04) per share, for a total transaction of £12,000 ($14,923.52).

Roquefort Therapeutics Trading Up 4.1 %

ROQ opened at GBX 2.40 ($0.03) on Friday. The company has a quick ratio of 3.07, a current ratio of 0.79 and a debt-to-equity ratio of 12.37. The firm has a market cap of £3.09 million, a price-to-earnings ratio of -239.50 and a beta of 0.05. The business’s 50 day moving average is GBX 3.96 and its two-hundred day moving average is GBX 3.98. Roquefort Therapeutics plc has a 52 week low of GBX 2.15 ($0.03) and a 52 week high of GBX 9.50 ($0.12).

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.